Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dactinomycin
Drug ID BADD_D00571
Description A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Indications and Usage For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen
Marketing Status approved; investigational
ATC Code L01DA01
DrugBank ID DB00970
KEGG ID D00214
MeSH ID D003609
PubChem ID 457193
TTD Drug ID D0P8IV
NDC Product Code 58623-0098; 68305-200; 66993-489; 71288-129; 68254-0017; 55292-811; 55150-431; 42658-008; 55150-928; 39822-2100
UNII 1CC1JFE158
Synonyms Dactinomycin | Meractinomycin | Actinomycin D | Actinomycin | Cosmegen | Cosmegen Lyovac | Lyovac, Cosmegen | Lyovac-Cosmegen | Lyovac Cosmegen | LyovacCosmegen
Chemical Information
Molecular Formula C62H86N12O16
CAS Registry Number 50-76-0
SMILES CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(= C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC 6=O)C(C)C)C)C)C(C)C)C)N)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Febrile neutropenia01.02.03.002; 08.05.02.004--
Feeling abnormal08.01.09.014---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Folliculitis11.02.01.053; 23.11.04.003--
Gastrointestinal pain07.01.05.005--
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.0010.000112%-
Hepatitis09.01.07.004---
Hepatomegaly09.01.05.001---
Hepatotoxicity09.01.07.009; 12.03.01.008---
Hypersensitivity10.01.03.003--
Hypocalcaemia14.04.01.004--
Ileus paralytic07.02.05.0010.000112%-
Infection11.01.08.002---
Joint contracture15.01.08.001---
Kidney malformation03.06.01.006; 20.01.06.004---
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Leukopenia01.02.02.001---
Liver function test abnormal13.03.04.030---
Malaise08.01.01.003--
Mouth ulceration07.05.06.004---
Mucosal inflammation08.01.06.0020.000112%-
Myalgia15.05.02.001--
Nausea07.01.07.001--
Necrosis08.03.03.001; 24.04.02.006---
Neuropathy peripheral17.09.03.0030.000112%-
Neutropenia01.02.03.0040.000168%-
Oedema08.01.07.006; 14.05.06.010---
Oesophagitis07.08.05.001--
Ovarian failure05.05.01.012; 21.11.02.0050.000112%-
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene